JaLCDOI 10.18926/AMO/31722
FullText URL fulltext.pdf
Author Nagai, Atsushi| Nasu, Yasutomo| Shirasaki, Yoshinori| Iguchi, Hiroki| Arata, Ryouji| Tsugawa, Masaya| Tsushima, Tomoyasu| Kumon, Hiromi|
Abstract <p>We performed laparoscopic prostatectomy in seven cases with organ-confined prostate cancer. In 6 cases, the surgery was completed successfully and the mean operative time was 424 min. Volume of blood loss was 200 to 3,200 ml and catheterization lasted 6 to 37 days. No major complications were observed in 6 of the cases. In one case, open surgical conversion was necessary mainly due to a bladder injury. Although these were the first cases of laparoscopic prostatectomy in our institution, the technical difficulty and complexity of the surgery were moderate. We believe that laparoscopic radical prostatectomy will become a standard option for the treatment of organ-confined prostate cancer.</p>
Keywords prosatatic cancer laparoscopy prostatectomy
Amo Type Article
Published Date 2002-02
Publication Title Acta Medica Okayama
Volume volume56
Issue issue1
Publisher Okayama University Medical School
Start Page 51
End Page 52
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 11873945
Web of Science KeyUT 000174031300009
JaLCDOI 10.18926/AMO/31973
FullText URL fulltext.pdf
Author Edamura, Kohei| Saika, Takashi| Senoh, Takashi| Koizumi, Fumihito| Manabe, Daisuke| Ebara, Shin| Kaku, Haruki| Yokoyama, Teruhiko| Abarzua, Fernando| Nagai, Atsushi| Nasu, Yasutomo| Tsushima, Tomoyasu| Kumon, Hiromi|
Abstract <p>This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100 percent for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81 percent 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93 percent and 100 percent cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79 percent rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease.</p>
Keywords prostate carcinoma long-term cohort retrospective outcome
Amo Type Article
Published Date 2005-10
Publication Title Acta Medica Okayama
Volume volume59
Issue issue5
Publisher Okayama University Medical School
Start Page 195
End Page 199
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 16286958
Web of Science KeyUT 000232835600003
JaLCDOI 10.18926/AMO/30945
FullText URL fulltext.pdf
Author Kobayashi, Tomoko| Sakaguchi, Masakiyo| Tanimoto, Ryuta| Abarzua, Fernando| Takaishi, Mikiro| Kaku, Haruki| Kataoka, Ken| Saika, Takashi| Nasu, Yasutomo| Miyazaki, Masahiro| Kumon, Hiromi| Huh, Nam-ho|
Abstract <p>We have recently shown that a new therapeutic modality using the REIC/Dkk-3 gene (Ad-REIC) is effective against various human cancers, including those of prostate, testis and breast origins. The aim of the present study was to examine the sensitivity of bladder cancers to Ad-REIC and to clarify the molecular mechanisms that determine sensitivity/resistance. We found that 2 human bladder cancer cell lines, T24 and J82, are resistant to Ad-REIC. In T24 and J82 cells, the ER stress response and activation of JNK were observed in a manner similar to that in the sensitive PC3 cells. Translocation of Bax to mitochondria occurred in PC3 cells but not in T24 and J82 cells. Bcl-2 was remarkably overexpressed in T24 and J82 compared with the expression levels in sensitive cell lines. Treatment of T24 and J82 cells with a Bcl-2 inhibitor sensitized the cells to Ad-REIC-induced apoptosis. The results indicate that some human bladder cancers are resistant to apoptosis induced by overexpression of REIC/Dkk-3, which is at least in part due to up-regulation of Bcl-2. These results provide a basis for possible use of Bcl-2 as a marker of sensitive cancers and to try to sensitize resistant cancers to Ad-REIC by down-regulation of Bcl-2.</p>
Keywords REIC/Dkk-3 bladder cancer apoptosis Bcl-2
Amo Type Original Article
Published Date 2008-12
Publication Title Acta Medica Okayama
Volume volume62
Issue issue6
Publisher Okayama University Medical School
Start Page 393
End Page 401
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
Web of Science KeyUT 000262025000006
Author Yokoyama, Teruhiko| Watanabe, Toyohiko| Saika, Takashi| Nasu, Yasutomo| Kumon, Hiromi| Miyaji, Yoshiyuki| Nagai, Atsushi|
Published Date 2007-10-02
Publication Title International Journal of Urology
Volume volume14
Issue issue7
Content Type Journal Article
JaLCDOI 10.18926/AMO/32868
FullText URL fulltext.pdf
Author Arata, Ryoji| Saika, Takashi| Tsushima, Tomoyasu| Abarzua, Fernando| Nasu, Yasutomo| Kumon, Hiromi|
Abstract To compare the quality of life (QOL) in patients with ileal neobladder and sigmoidal neobladder, a retrospective survey was conducted using a formulated questionnaire. Between January and March 1999, a QOL survey was conducted using self-administered questionnaires (EORTC QLQ-C30, IPSS, supplemented with detailed questionnaires about continence, sexual function, and patient’s satisfaction with the selected urinary diversion method) for 78 patients with orthotopic urinary reservoir (OUR) who were followed-up for more than 3 months after cystectomy. Among 78 patients, 63 had OUR using an ileal segment (male/female&#65309;59/4, median age: 70.8 years old, median follow-up: 1.7 years). Fifteen patients had OUR using a sigmoidal segment (male/female&#65309;13/2, median age: 71.9, median follow-up: 3.9). The QLQ-C30 functional evaluation and the items in relation to sexual function showed no diff erences between the 2 groups. Concerning the voiding condition, bladder emptying, frequency, and urgency, scores in the sigmoidal OUR group were signifi cantly higher. The QOL score concerning voiding conditions, daytime, and nighttime continence and quantity of pad showed a better score in the ileal OUR group. Concerning the satisfaction with methods of urinary diversion, patients in the sigmoidal OUR group expressed less satisfaction than their preoperative expectations. Considering several postoperative voiding conditions, ileal OUR seems superior to sigmoidal OUR.
Keywords urinary diversion orthotopic urinary reservoirs bladder cancer quality of life
Amo Type Original Article
Published Date 2007-08
Publication Title Acta Medica Okayama
Volume volume61
Issue issue4
Publisher Okayama University Medical School
Start Page 229
End Page 234
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 17726512
Web of Science KeyUT 000248957100007
Author Sakaguchi, Masakiyo| Kataoka, Ken| Abarzua, Fernando| Tanimoto, Ryuta| Watanabe, Masami| Murata, Hitoshi| Than, Swe Swe| Kurose, Kaoru| Kashiwakura, Yuji| Ochiai, Kazuhiko| Nasu, Yasutomo| Kumon, Hiromi| Huh, Nam-ho|
Published Date 2009-05-22
Publication Title The Journal of Biological Chemistry
Volume volume284
Issue issue21
Content Type Journal Article
Author Huang, P| Kaku, H| Chen, J| Kashiwakura, Y| Saika, T| Nasu, Y| Urata, Y| Fujiwara, T| Watanabe, M| Kumon, H|
Published Date 2010-07
Publication Title Cancer Gene Therapy
Volume volume17
Issue issue7
Content Type Journal Article
JaLCDOI 10.18926/AMO/48076
FullText URL 66_1_7.pdf
Author Kawauchi, Keiichiro| Watanabe, Masami| Kaku, Haruki| Huang, Peng| Sasaki, Kasumi| Sakaguchi, Masakiyo| Ochiai, Kazuhiko| Huh, Nam-ho| Nasu, Yasutomo| Kumon, Hiromi|
Abstract The preclinical safety and therapeutic efficacy of adenoviral vectors that express the REIC/Dkk-3 tumor suppressor gene (Ad-REIC) was examined for use in prostate cancer gene therapy. The Ad-human (h) and mouse (m) REIC were previously demonstrated to induce strong anti-cancer effects in vitro and in vivo, and we herein report the results of two in vivo studies. First, intra-tumor Ad-hREIC administration was examined for toxicity and therapeutic effects in a subcutaneous tumor model using the PC3 prostate cancer cell line. Second, intra-prostatic Ad-mREIC administration was tested for toxicity in normal mice. The whole-body and spleen weights, hematological and serum chemistry parameters, and histological evaluation of tissues from throughout the body were analyzed. Both experiments indicated that there was no significant difference in the examined parameters between the Ad-REIC-treated group and the control (PBS- or Ad-LacZ-treated) group. In the in vitro analysis using PC3 cells, a significant apoptotic effect was observed after Ad-hREIC treatment. Confirming this observation, the robust anti-tumor efficacy of Ad-hREIC was demonstrated in the in vivo subcutaneous prostate cancer model. Based on the results of these preclinical experiments, we consider the adenovirus-mediated REIC/Dkk-3 in situ gene therapy to be safe and useful for the clinical treatment of prostate cancer.
Keywords REIC Dickkopf-3 gene therapy prostate cancer preclinical study
Amo Type Original Article
Published Date 2012-02
Publication Title Acta Medica Okayama
Volume volume66
Issue issue1
Publisher Okayama University Medical School
Start Page 7
End Page 16
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2012 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 22358134
Web of Sience KeyUT 000300800700002
JaLCDOI 10.18926/AMO/32862
FullText URL 64_1_27.pdf
Author Kobayashi, Yasuyuki| Saika, Takashi| Manabe, Daisuke| Nasu, Yasutomo| Kumon, Hiromi|
Abstract We analyzed the prognostic factors influencing survival after surgeries for upper urinary tract urothelial carcinoma (UUT-UC) with longer follow-up periods than in previous studies. Between January 2000 and December 2004, 386 patients underwent nephroureterectomy for UUT-UC. The data for the 221 patients with UUT-UC were retrospectively reviewed. Nine variables were evaluated for association with the survival outcomes of cause-specific survival. The prognostic significance was tested univariately with the log-rank test. The simultaneous effects of multiple prognostic factors were estimated by multiple regression analysis using the Cox proportional hazards model. The median follow-up was 38.4 months. The 5-year over all survival was 62.3%. Significant prognostic factors for disease-specific survival rate on univariate analysis were pathological stage (p0.0001), tumor grade (p0.0324), and venous invasion (p0.0001). Multivariate analysis revealed that only venous invasion was significant for disease-specific survival rate (p0.0205). Venous invasion was the only independent prognostic factor in pathologically localized UUT-UC.
Keywords nephroureterectomy transitional cell carcinoma upper urinary tract
Amo Type Original Article
Note <a href="http://ousar.lib.okayama-u.ac.jp/amo/vol65/iss2/11">Erratum with Corrected and Republished Article</a>|
Published Date 2010-02
Publication Title Acta Medica Okayama
Volume volume64
Issue issue1
Publisher Okayama University Medical School
Start Page 27
End Page 31
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2010 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 20200581
Web of Science KeyUT 000274868300004
JaLCDOI 10.18926/AMO/31847
FullText URL fulltext.pdf
Author Kobuke, Makoto| Saika, Takashi| Nakanishi, Yoshiko| Ebara, Shin| Manabe, Daisuke| Uesugi, Tatsuya| Nose, Hiroyuki| Arata, Ryoji| Tsushima, Tomoyasu| Nasu, Yasutomo| Kumon, Hiromi|
Abstract <p>To determine health-related quality of life (HRQOL) after radical retropubic prostatectomy (RRP) or permanent prostate brachytherapy (BT), third party-conducted QOL surveys were prospectively compared. Between 2004 and 2005, 37 patients underwent RRP and 36 were treated with BT. A QOL survey consisting of the Medical Outcomes Study 36-Item Short Form (SF-36), the University of California, Los Angeles, Prostate Cancer Index (UCLA-PCI) and the International Prostate Symptoms Score (IPSS) was completed prospectively by a research coordinator at baseline, and at 1, 3, 6 and 12 months after treatment. The RRP patients scored well in general QOL except at 1 month after surgery, with their mental health better than at baseline by 6 months after surgery. Disease-specific QOL in RRP patients received a low score at 1 month for both urinary and sexual function, though urinary function rapidly recovered to baseline levels. BT patient QOL was not affected by the therapy except in the IPSS score. However, general and mental health scores in BT patients were inferior to those in RRP patients. This prospective study revealed differences in QOL after RRP and BT. These results will be helpful in making treatment decisions.</p>
Keywords prostate cancer radical prostatectomy QOL brachytherapy
Amo Type Original Article
Published Date 2009-06
Publication Title Acta Medica Okayama
Volume volume63
Issue issue3
Publisher Okayama University Medical School
Start Page 129
End Page 135
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 19571899
Web of Science KeyUT 000267388200002
JaLCDOI 10.18926/AMO/52142
FullText URL 68_1_35.pdf
Author Araki, Motoo| Jeong, Wooju| Park, Sung Yul| Lee, Young Hoon| Nasu, Yasutomo| Kumon, Hiromi| Hong, Sung Joon| Rha, Koon Ho|
Abstract The purpose of this study was to compare the positive surgical margin (PSM) rates of 2 techniques of robot-assisted radical prostatectomy (RARP) for pT2 (localized) prostate cancer. A retrospective analysis was conducted of 361 RARP cases, performed from May 2005 to September 2008 by a single surgeon (KHR) at our institution (Yonsei University College of Medicine). In the conventional technique, the bladder neck was transected first. In the modified ultradissection, the lateral border of the bladder neck was dissected and then the bladder neck was transected while the detrusor muscle of the bladder was well visualized. Perioperative characteristics and outcomes and PSM rates were analyzed retrospectively for pT2 patients (n=217), focusing on a comparison of those undergoing conventional (n=113) and modified ultradissection (n=104) techniques. There was no difference between the conventional and modified ultradissection group in mean age, BMI, PSA, prostate volume, biopsy Gleason score, and DʼAmico prognostic criteria distributions. The mean operative time was shorter (p<0.001) and the estimated blood loss was less (p<0.01) in the modified ultradissection group. The PSM rate for the bladder neck was significantly reduced by modified ultradissection, from 6.2% to 0% (p<0.05). In conclusion, modified ultradissection reduces the PSM rate for the bladder neck.
Keywords robot-assisted radical prostatectomy prostate cancer surgery surgical margin technique
Amo Type Original Article
Published Date 2014-02
Publication Title Acta Medica Okayama
Volume volume68
Issue issue1
Publisher Okayama University Medical School
Start Page 35
End Page 41
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 24553487
Web of Science KeyUT 000331592800006
JaLCDOI 10.18926/AMO/32881
FullText URL fulltext.pdf
Author Murakami, Takanori| Ebara, Shin| Saika, Takashi| Irie, Shin| Takeda, Katsuji| Maki, Yoshio| Miyaji, Sadayuki| Manabe, Daisuke| Kaku, Haruki| Nasu, Yasutomo| Tsushima, Tomoyasu| Kumon, Hiromi|
Abstract <p>We evaluated the need for transurethral biopsy at first follow-up after intravesical bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. The records of 84 patients with superficial bladder cancer who received a 6- or 8-week course of BCG were reviewed. Pathological results before BCG, cystoscopic findings, urinary cytology, and biopsy results for evaluation of BCG therapy were reviewed. All 19 patients with positive urinary cytology had evidence of positive bladder biopsy results. Fifty-three of 54 patients (98.1%) with no visible recurrent tumor and negative urinary cytology demonstrated negative pathological results on bladder biopsy. When not found in conjunction with positive urinary cytology, erythematous mucosa on cystoscopy was not an indicator of tumor recurrence or residual cancer. In conclusion, routine transurethral biopsy of the bladder for evaluating the response to BCG intravesical therapy is not necessary in patients who have no visible tumor on cystoscopy and negative urinary cytology./</p>
Keywords bladder cancer BCG therapy transurethral biopsy cystoscopy urinary cytology
Amo Type Original Article
Published Date 2007-12
Publication Title Acta Medica Okayama
Volume volume61
Issue issue6
Publisher Okayama University Medical School
Start Page 341
End Page 344
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 18183079
JaLCDOI 10.18926/AMO/31976
FullText URL fulltext.pdf
Author Nagai, Atsushi| Tokuyama, Eijirou| Nanba, Yuzaburo| Tsutsui, Tetsuya| Kimata, Yoshihiro| Nakatsuka, Mikiya| Koshima, Isao| Saika, Takashi| Nasu, Yasutomo| Kumon, Hiromi|
Abstract <p>The first case of sex reassignment surgery (SRS) in our hospital was performed in January 2001; as of February, 2005, 4 cases of MTF-SRS had been performed. In the 2 most recent cases, we used penile and scrotal skin flaps to avoid complications. The depth and width of the new vagina was made to be adequate for sexual intercourse. Future attention should be focused on devising a surgical technique that will help prevent the complications of partial necrosis of the epidermal skin and wound dehiscence. Although ours is only an initial experience, we describe our surgical technique herein.</p>
Keywords gender identity disorder sex reassignment surgery male to female transsexual
Amo Type Article
Published Date 2005-10
Publication Title Acta Medica Okayama
Volume volume59
Issue issue5
Publisher Okayama University Medical School
Start Page 231
End Page 233
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 16286961
Web of Sience KeyUT 000232835600008
JaLCDOI 10.18926/AMO/47013
FullText URL 65_5_315.pdf
Author Wang, Lei| Kaku, Haruki| Huang, Peng| Xu, Kexin| Yang, Kai| Zhang, Jiheng| Li, Ming| Xie, Liping| Wang, Xiaofeng| Sakai, Akiko| Watanabe, Masami| Nasu, Yasutomo| Shimizu, Kenji| Kumon, Hiromi| Na, Yanqun|
Abstract Deficiencies in the human DNA repair gene WRN are the cause of Werner syndrome, a rare autosomal recessive disorder characterized by premature aging and a predisposition to cancer. This study evaluated the association of WRN Leu1074Phe (rs1801195), a common missense single nucleotide polymorphism in WRN, with prostate cancer susceptibility in Chinese subjects. One hundred and forty-seven prostate cancer patients and 111 male cancer-free control subjects from 3 university hospitals in China were included. Blood samples were obtained from each subject, and the single nucleotide polymorphism WRN Leu1074Phe was genotyped by using a Snapshot assay. The results showed that WRN Leu1074Phe was associated with the risk of prostate cancer in Chinese men and that the TG/GG genotype displayed a decreased prevalence of prostate cancer compared with the TT genotype (OR=0.58, 95%CI:0.35-0.97, p=0.039). Through stratified analysis, more significant associations were revealed for the TG/GG genotype in the subgroup with diagnosis age <_ 72 yr (OR=0.27, 95%CI:0.12-0.61, p=0.002) and in patients with localized diseases (OR=0.36, 95%CI:0.19-0.70, p=0.003). However, no statistically significant difference was found in the subgroup with age >72 yr or in patients with advanced diseases. We concluded that the genetic variant Leu1074Phe in the DNA repair gene WRN might play a role in the risk of prostate cancer in Chinese subjects.
Keywords polymorphism prostatic neoplasms single nucleotide susceptibility WRN
Amo Type Original Article
Published Date 2011-10
Publication Title Acta Medica Okayama
Volume volume65
Issue issue5
Publisher Okayama University Medical School
Start Page 315
End Page 323
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2011 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 22037267
Web of Science KeyUT 000296116400005
Author Kurahashi, Hiroaki| Watanabe, Masami| Sugimoto, Morito| Ariyoshi, Yuichi| Mahmood, Sabina| Araki, Motoo| Ishii, Kazushi| Nasu, Yasutomo| Nagai, Atsushi| Kumon, Hiromi|
Published Date 2013-12
Publication Title Endocrine Journal
Volume volume60
Issue issue12
Content Type Journal Article
JaLCDOI 10.18926/AMO/30939
FullText URL fulltext.pdf
Author Kobayashi, Yasuyuki| Saika, Takashi| Manabe, Daisuke| Nasu, Yasutomo| Kumon, Hiromi|
Abstract <p>The purpose of this study is to compare the performance of laparoscopic partial nephrectomy (LPN) with and without clamping of the renal artery and to evaluate the impact of clamping on postoperative renal function. A total of 20 patients underwent LPN, 13 without and 7 with clamping of the renal artery. The 2 groups were compared with respect to complications, blood loss, operative time, mean tumor size, and incidence of positive margins. Renal function was evaluated by pre- and postoperative renal scintigraphy using <sup>99m</sup>Technetium-mercaptoacetyltriglycine (<sup>99m</sup>Tc-MAG3). Intraoperative blood loss was significantly higher in the group without clamping than in the group with clamping (p0.04). In the group with clamping, the median warm ischemic time was 35min (range 25-40min). The serum creatinine values and the renal scintigraphy showed no influence on postoperative renal function with or without clamping. In the group without clamping, 2 cases were showed positive surgical margins. The procedure performed with clamping of the renal artery is superior to the procedure performed without clamping as it provides the advantages of controlling hemorrhaging without injury to renal function and prolonging the surgical time and allowing for more accurate resection of renal tumors.</p>
Keywords laparoscopic partial nephrectomy <sup>99m</sup>Tc-MAG3 renal function
Amo Type Original Article
Published Date 2008-08
Publication Title Acta Medica Okayama
Volume volume62
Issue issue4
Publisher Okayama University Medical School
Start Page 269
End Page 273
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 18766210
Web of Science KeyUT 000258680900007
JaLCDOI 10.18926/AMO/54982
FullText URL 71_2_135.pdf
Author Mori, Akihiro| Watanabe, Masami| Sadahira, Takuya| Kobayashi, Yasuyuki| Ariyoshi, Yuichi| Ueki, Hideo| Wada, Koichiro| Ochiai, Kazuhiko| Li, Shun-Ai| Nasu, Yasutomo|
Abstract The cluster of differentiation 147 (CD147), also known as EMMPRIN, is a key molecule that promotes cancer progression. We previously developed an adenoviral vector encoding a tumor suppressor REIC/Dkk-3 gene (Ad-REIC) for cancer gene therapy. The therapeutic effects are based on suppressing the growth of cancer cells, but, the underlying molecular mechanism has not been fully clarified. To elucidate this mechanism, we investigated the effects of Ad-REIC on the expression of CD147 in LNCaP prostate cancer cells. Western blotting revealed that the expression of CD147 was significantly suppressed by Ad-REIC. Ad-REIC also suppressed the cell growth of LNCaP cells. Since other researchers have demonstrated that phosphorylated mitogen-activated protein kinases (MAPKs) and c-Myc protein positively regulate the expression of CD147, we investigated the correlation between the CD147 level and the activation of MAPK and c-Myc expression. Unexpectedly, no positive correlation was observed between CD147 and its possible regulators, suggesting that another signaling pathway was involved in the downregulation of CD147. This is the first study to show the downregulation of CD147 by Ad-REIC in prostate cancer cells. At least some of the therapeutic effects of Ad-REIC may be due to the downregulation of the cancer-progression factor, CD147.
Keywords prostate cancer REIC/Dkk-3 CD147 cell growth p38 MAP kinase
Amo Type Original Article
Published Date 2017-04
Publication Title Acta Medica Okayama
Volume volume71
Issue issue2
Publisher Okayama University Medical School
Start Page 135
End Page 142
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28420895
JaLCDOI 10.18926/AMO/32878
FullText URL fulltext.pdf
Author Ebara, Shin| Manabe, Daisuke| Kobayashi, Yasuyuki| Tanimoto, Ryuta| Saika, Takashi| Nasu, Yasutomo| Saito, Shirou| Satoh, Takefumi| Miki, Kenta| Hashine, Katsuyoshi| Kumon, Hiromi|
Abstract <p>From September 2003 to December 2005, 188 patients who visited our hospital and allied institutions for the purpose of prostate brachytherapy were administrated hormonal therapy for volume reductions before brachytherapy. The pretreatment and posttreatment of prostate volume using a transrectal ultrasound volumetric study and the types and duration of hormonal therapy were analyzed. We administered 91 patients with Luteinizing hormone-releasing hormone (LH-RH) agonist, 49 patients with anti-androgen (bicaltamide/flutamide), and 48 patients with maximum androgen blockade (MAB). The duration of the hormonal therapy was 1-3 months for 49 patients, 4-6 months for 59 patients, 7-9 months for 40 patients, 10-12 months for 32 patients, and over 13 months for 8 patients. Before the initiation of hormonal therapy, the mean prostate volume was 35.12 ml (11.04-78.71 ml), and the average of prostate volume before and after hormonal therapy was 36.79 ml and 24.79 ml, respectively (a 32.4% reduction). The prostate volume reduction rate was 32.0% for the LH-RH agonist only, 18.1% for the anti-androgen only and 41.2% for the MAB. No statistically significant difference was observed for the duration of hormonal therapy between 3 groups. A three-month course of the neoadjuvant LH-RH agonist indicated a sufficient volume reduction effectiveness for a large prostate volume.</p>
Keywords androgen deprivation therapy brachytherapy localized prostate cancer prostate volume reduction
Amo Type Original Article
Published Date 2007-12
Publication Title Acta Medica Okayama
Volume volume61
Issue issue6
Publisher Okayama University Medical School
Start Page 335
End Page 340
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 18183078
Web of Science KeyUT 000251943800004
JaLCDOI 10.18926/AMO/54507
FullText URL 70_4_295.pdf
Author Araki, Motoo| Wada, Koichiro| Mitsui, Yosuke| Kubota, Risa| Yoshioka, Takashi| Ariyoshi, Yuichi| Kobayashi, Yasuyuki| Kitagawa, Masashi| Tanabe, Katsuyuki| Sugiyama, Hiroshi| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo|
Abstract Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
Keywords end-stage renal disease immunosuppression kidney transplantation
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 295
End Page 297
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549676
Web of Science KeyUT 000384748600011
Author Ochiai, Kazuhiko| Watanabe, Masami| Ueki, Hideo| Huang, Peng| Fujii, Yasuyuki| Nasu, Yasutomo| Noguchi, Hirofumi| Hirata, Takeshi| Sakaguchi, Masakiyo| Huh, Nam-ho| Kashiwakura, Yuji| Kaku, Haruki| Kumon, Hiromi|
Published Date 2011-08-26
Publication Title Biochemical and Biophysical Research Communications
Volume volume412
Issue issue2
Content Type Journal Article